The Asston Pharmaceuticals IPO marks the public debut of a Navi Mumbai-based pharmaceutical and nutraceutical company, opening for subscription from July 9 to July 11, 2025. With an issue size of ₹27.56 crore through a fresh issue of 22.41 lakh shares, the IPO will list on the BSE SME platform. Asston Pharmaceuticals manufactures and exports a diverse range of products—including tablets, capsules, syrups, and sachets—serving both domestic and international markets. Proceeds from the Asston Pharmaceuticals IPO will be used for capital expenditure, working capital, debt repayment, and general corporate purposes, supporting the company’s expansion and operational growth.
₹30
₹123
₹119.00
Expert Opinions
The Asston Pharmaceuticals IPO is attracting cautious optimism in the market, backed by the company’s impressive financial metrics and growth trajectory. Key strengths include a diversified product portfolio spanning pharmaceutical and nutraceutical segments, a WHO-GMP certified manufacturing facility, and expanding export markets in Africa and Asia. For FY 2025, the Asston Pharmaceuticals IPO shows a stellar Return on Equity (ROE) of 50.56%, Return on Capital Employed (ROCE) of 51.25%, and a Net Asset Value (NAV) of ₹17.09, reflecting strong profitability and efficient capital use.
Risks include competition in the pharmaceutical sector, regulatory compliance challenges, and dependence on export markets. From a long-term investment perspective, Asston’s robust fundamentals and growth potential make it an attractive option, especially for investors seeking exposure to emerging pharmaceutical companies with scalable operations and strong financial discipline.
Investor Considerations
Investors evaluating the Asston Pharmaceuticals IPO should note the company’s strong fundamentals, with FY 2025 revenue growing 61.7% to ₹25.61 crore and PAT rising to ₹4.33 crore, reflecting robust operational efficiency and expanding market presence. The pharmaceutical and nutraceutical sector outlook is positive, driven by rising healthcare demand and export opportunities in emerging markets.
For FY 2025, the Asston Pharmaceuticals IPO is valued at a Price to Book Value of 12.07, PAT margin of 17.27%, and a moderate Debt/Equity ratio of 0.68. Growth prospects are supported by product diversification, global certifications, and a growing export footprint. However, risks include regulatory compliance, competition, and dependency on select international markets. While short-term gains may occur, the IPO is best suited for long-term investors seeking exposure to a high-growth, export-oriented pharma company with strong profitability metrics.
| Date | GMP | Trend |
|---|---|---|
| 15 Jul 2025 19.52 | ₹30 | --- |
| 14 Jul 2025 11.06 | ₹30 | --- |
| 13 Jul 2025 15.25 | ₹30 | --- |
| 12 Jul 2025 15.59 | ₹30 | --- |
| 11 Jul 2025 10.14 | ₹30 | --- |
| 10 Jul 2025 13.44 | ₹30 | Up |
| 09 Jul 2025 15.37 | ₹20 | Up |
| 07 Jul 2025 19.36 | ₹10 | --- |
FAQs
The Grey Market Premium showed poor accuracy in predicting Asston Pharmaceuticals IPO’s listing performance. Despite a final GMP of ₹30, signaling a robust expected premium of 24.39% over the issue price of ₹123, the stock disappointed by listing at ₹119, reflecting a negative return of -3.25%. With a large prediction error of 27.64%, the GMP not only failed to predict the correct direction but also vastly overestimated the gains, indicating low reliability in this instance.
Asston Pharmaceuticals IPO Current GMP is ₹30.
Asston Pharmaceuticals IPO Expected Returns is 24.39%.
Asston Pharmaceuticals IPO estimated listing price is ₹153.